MXCT
Maxcyte, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EBITDA non-GAAP | -$5.1M | first quarter of 2026 | — |
| Non-GAAP adjusted gross margin non-GAAP | 78% | first quarter of 2026 | — |
| SeQure total revenue | $600K | Q1 2026 call | — |
| share repurchase program authorization | $10M | Q1 2026 call | — |
| SPL partners | 29 | Q1 2026 call | — |
| SPL programs currently in the clinic | 12 | Q1 2026 call | — |
| total future pre-commercial milestone opportunity | $100M | Q1 2026 call | — |
| Total cash, cash equivalents and investments | $155.6M | As of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MXCT
this stock
Maxcyte, Inc.
|
$144.61M | -12.9% | -14.5% | — | 1.4% |
|
ABT
Abbott Laboratories
|
$173.73B | -20.7% | +5.7% | 27.9 | 1.3% |
|
SYK
Stryker Corp
|
$126.97B | -5.5% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MXCT | +5.5% | +18.4% | +8.0% | +9.8% | -12.9% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | +5.6% | +18.4% | -1.0% | +9.2% | -23.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.